On November 26, 2025 Mural Oncology plc (Nasdaq: MURA) ("Mural") reported that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural announced on August 20, 2025 (the "Transaction Agreement"), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition (as defined below) will be $2.035 in cash per share.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously announced on August 20, 2025, XOMA Royalty, Sub and Mural entered into the Transaction Agreement pursuant to which Sub, a wholly-owned subsidiary of XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural (the "Acquisition") pursuant to an Irish High Court sanctioned "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014 (the "Scheme").

The Acquisition is expected to close in early December 2025, subject to the satisfaction of the outstanding closing conditions and the sanction of the Scheme by the Irish High Court.

(Press release, Mural Oncology, NOV 26, 2025, View Source [SID1234660975])

On November 25, 2025 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

(Press release, Fate Therapeutics, NOV 25, 2025, View Source [SID1234660942])

On November 25, 2025 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, reported that Dr. Neal Walker, Aclaris’ Chief Executive Officer and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December 2, 2025 at 11:00 AM EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast will be accessible on the Events page of View Source The webcast will be available on the Aclaris website for at least 30 days.

(Press release, Aclaris Therapeutics, NOV 25, 2025, View Source [SID1234660927])

On November 25, 2025 Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to eliminate cancer, reported the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest dose concentration of PH-762. Pathology results for these patients are expected in Q1 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PH-762 is a potent silencer of the PD-1 gene implicated in various forms of skin cancer.

The Phase 1b clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. Per the trial’s protocol, patients receive four injections of PH-762 at weekly intervals and pathologic response is assessed on day 36 after the initial injection of PH-762 (NCT# 06014086).

Thus far, a total of 18 patients with cutaneous carcinomas have completed treatment across five dose escalating cohorts in the Phase 1b trial. The cumulative pathologic response in 16 patients with cSCC include six with a complete response (100% clearance), two with a near complete response (> 90% clearance) and two with a partial response (> 50% clearance). A single patient with metastatic Merkel cell carcinoma had a partial response (> 50% clearance). Six patients with cSCC and one patient with metastatic melanoma had a pathologic non-response (< 50% clearance). No patients in the study have exhibited clinical progression of disease.

To date, there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients receiving intratumoral PH-762 in this trial. Moreover, PH-762 has been well tolerated in all enrolled patients in each escalating dose cohort.

"Completing enrollment in the Phase 1b trial for PH-762 marks a significant step forward in advancing a promising treatment option for skin cancer." said Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals. "We are deeply grateful to the patients, investigators, our partners, and our team for their help in successfully achieving this important milestone."

(Press release, Phio Pharmaceuticals, NOV 25, 2025, View Source [SID1234660943])

On November 25, 2025 Alkermes plc (Nasdaq: ALKS) reported that management will participate in two upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

8th Annual Evercore Healthcare Conference
Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT)

Piper Sandler 37th Annual Healthcare Conference
Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

(Press release, Alkermes, NOV 25, 2025, View Source [SID1234660928])